Metagenomi Therapeutics Inc (MGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 41,722 | 27,386 | 140,603 | 184,441 | 39,296 |
| Marketable Securities | 119,077 | 220,921 | 130,579 | 177,690 | 68,858 |
| Receivables | 305 | 1,257 | 2,451 | N/A | N/A |
| Other current assets | 0 | 0 | 0 | 1,274 | 0 |
| TOTAL | $165,538 | $257,960 | $278,273 | $366,899 | $108,916 |
| Non-Current Assets | |||||
| PPE Net | 12,288 | 17,740 | 21,542 | 16,522 | 3,862 |
| Investments And Advances | 2,154 | 3,447 | 10,676 | 7,806 | 6,417 |
| Other Non-Current Assets | 41,123 | 45,452 | 54,351 | 23,259 | 22,797 |
| TOTAL | $55,565 | $66,639 | $86,569 | $47,587 | $33,076 |
| Total Assets | $221,103 | $324,599 | $364,842 | $414,486 | $141,992 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,489 | 533 | 1,791 | 2,011 | 1,354 |
| Accrued Expenses | 6,719 | 8,422 | 11,472 | 8,790 | 3,531 |
| Other current liabilities | N/A | N/A | 837 | 743 | 3,559 |
| TOTAL | $22,933 | $37,309 | $68,861 | $48,537 | $25,172 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 8,700 | 22,762 | 48,068 | 33,942 | 16,041 |
| Other Non-Current Liabilities | 36,585 | 42,196 | 49,881 | 18,089 | 49,153 |
| TOTAL | $39,574 | $52,433 | $80,807 | $94,274 | $72,869 |
| Total Liabilities | $62,507 | $89,742 | $149,668 | $142,811 | $98,041 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 37,621 | 37,383 | N/A | N/A | N/A |
| Common Shares | 4 | 4 | N/A | 26 | 26 |
| Retained earnings | -310,870 | -223,002 | -144,944 | -76,689 | -33,096 |
| Other shareholders' equity | 260 | 709 | 350,661 | 348,338 | 77,021 |
| TOTAL | $158,596 | $234,857 | $215,174 | $271,675 | $43,951 |
| Total Liabilities And Equity | $221,103 | $324,599 | $364,842 | $414,486 | $141,992 |